Vaccine developers have long struggled with creating platforms that simultaneously trigger both antibody production and robust T-cell responses, particularly the elusive CD8+ killer T cells that eliminate infected cells. This breakthrough represents a fundamental shift from current vaccine architectures toward precisely engineered nanostructures that orchestrate immune activation at the molecular level. The DoriVac platform employs DNA origami—folded DNA structures that serve as scaffolds—to position viral antigens and immune-stimulating adjuvants at exact nanometer distances. This spatial precision mimics how viruses naturally present antigens, triggering more comprehensive immune recognition. Testing against SARS-CoV-2, HIV, and Ebola revealed superior activation of CD8+ T cells compared to conventional formulations, alongside robust antibody and CD4+ helper T cell responses. The technology targets highly conserved viral regions that remain stable across variants, potentially addressing one of vaccination's persistent challenges: immune escape through viral mutation. Human cell studies using organ-on-chip technology confirmed the platform's ability to activate both arms of adaptive immunity. When loaded with full-length SARS-CoV-2 spike protein, DoriVac matched mRNA vaccine performance while offering improved thermal stability. This modular approach represents a significant engineering advance in immunology, moving beyond traditional adjuvant mixing toward precise molecular choreography. The ability to simultaneously engage multiple immune pathways could prove transformative for diseases where current vaccines provide incomplete protection. However, the technology remains in preclinical development, requiring extensive safety evaluation and optimization for human use. The platform's versatility suggests applications beyond infectious diseases, potentially extending to cancer immunotherapy and autoimmune conditions.